Faculty Position in Neurobiology Swansea University, Department of Molecular Neurobiology

The Institute of Life Science at Swansea University Medical School performs translational research into basic mechanisms of human diseases. Applications are invited from ambitious, self-motivated candidates to join our Molecular Neurobiology research group to enhance our understanding of how the peptide hormone, ghrelin, may be used as a potential therapy for treating cognitive decline and dementia. Recent work from our laboratory (and others) suggests that this hormone plays an important regenerative (Kent et al.2015 Psychoneuroendo; Hornsby et al.2016 Psychoneuroendo) and protective (Bayliss et al.2016 J.Neurosci) role in the adult brain. This project will develop novel small molecule compounds (aided by in-silico drug design) with the purpose of modulating the ghrelin-axis to regenerate and protect the brain. The therapeutic potential of these compounds will be assessed using both in-vitro and in-vivo models. It is expected that lead compounds will be validated using behavioural and neurochemical assessments in pre-clinical models of Alzheimer’s disease performed in collaboration with Professor Mark Good of Cardiff University. This project is funded by Life Sciences Research Network Wales (LSRNW) and Swansea University Medical School. Swansea University was ranked 2nd out of 94 UK Higher Education Institutions for research in Allied Health Professions (REF 2014). Additional information about research in the Medical School can be found athttp://www.swansea.ac.uk/medicine/research/ and information about research in Dr Davies’ lab can be found at http://www.swansea.ac.uk/staff/medicine/learningandteaching/j.s.davies/. The successful candidate is expected to start their studentship on 1st October 2016. Academic Requirements: Applicants should have (or expect to achieve) a minimum of a first class or 2.1 degree in Neuroscience, Pharmacology or a relevant subject. Experience of computer-aided drug discovery, neurochemistry and/or behavioural assessment of cognition would be beneficial. Applicants with a Master's level qualification will also be considered. Residency Criteria: Due to funding restrictions, this studentship is open to UK/EU candidates only. If you apply for this position please say you saw it on Psychoneuroxy

The Institute of Life Science at Swansea University Medical School performs translational research into basic mechanisms of human diseases.

Applications are invited from ambitious, self-motivated candidates to join our Molecular Neurobiology research group to enhance our understanding of how the peptide hormone, ghrelin, may be used as a potential therapy for treating cognitive decline and dementia. Recent work from our laboratory (and others) suggests that this hormone plays an important regenerative (Kent et al.2015 Psychoneuroendo; Hornsby et al.2016 Psychoneuroendo) and protective (Bayliss et al.2016 J.Neurosci) role in the adult brain.

This project will develop novel small molecule compounds (aided by in-silico drug design) with the purpose of modulating the ghrelin-axis to regenerate and protect the brain. The therapeutic potential of these compounds will be assessed using both in-vitro and in-vivo models. It is expected that lead compounds will be validated using behavioural and neurochemical assessments in pre-clinical models of Alzheimer’s disease performed in collaboration with Professor Mark Good of Cardiff University.

This project is funded by Life Sciences Research Network Wales (LSRNW) and Swansea University Medical School.

Swansea University was ranked 2nd out of 94 UK Higher Education Institutions for research in Allied Health Professions (REF 2014).

Additional information about research in the Medical School can be found athttp://www.swansea.ac.uk/medicine/research/ and information about research in Dr Davies’ lab can be found at http://www.swansea.ac.uk/staff/medicine/learningandteaching/j.s.davies/.

The successful candidate is expected to start their studentship on 1st October 2016.

Academic Requirements:

Applicants should have (or expect to achieve) a minimum of a first class or 2.1 degree in Neuroscience, Pharmacology or a relevant subject. Experience of computer-aided drug discovery, neurochemistry and/or behavioural assessment of cognition would be beneficial. Applicants with a Master's level qualification will also be considered.

Residency Criteria:

Due to funding restrictions, this studentship is open to UK/EU candidates only.

If you apply for this position please say you saw it on Psychoneuroxy